Sandoz to invest $90M in Slovenia site that will produce biosimilars
Sandoz is investing $90 million to build a biosimilar development center in Ljubljana, Slovenia, the second major investment that the generics maker has made in the country so far this year.
Sandoz plans to build a new facility that is expected to bolster its capabilities to produce drug substances and develop biosimilars, the company said in a press release. It plans to create 200 new jobs at the center, which is set to be completed by 2026.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.